Virtual Reality Hemifield Measurements for Corrective Surgery Eligibility in Ptosis Patients: A Pilot Clinical Trial.
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
03 10 2022
03 10 2022
Historique:
entrez:
25
10
2022
pubmed:
26
10
2022
medline:
28
10
2022
Statut:
ppublish
Résumé
We developed an accelerated virtual reality (VR) suprathreshold hemifield perimetry algorithm, the median cut hemifield test (MCHT). This study examines the ability of the MCHT to determine ptosis severity and its reversibility with an artificial improvement by eyelid taping on an HTC Vive Pro Eye VR headset and the Humphrey visual field analyzer (HVFA) to assess the capabilities of emerging technologies in evaluating ptosis. In a single visit, the MCHT was administered along with the HVFA 30-2 on ptotic untaped and taped eyelids in a randomized order. The primary end points were a superior field visibility comparison with severity of VF loss and VF improvement after taping for MCHT and HVFA. Secondary end points included evaluating patients' Likert-scaled survey responses on the comfort, speed, and overall experience with both testing modalities. VR's MCHT superior field degrees visible correlated well for severe category margin to reflex distance (r = 0.78) compared with HVFA's (r = -0.21). The MCHT also demonstrated noninferiority (83.3% agreement; P = 1) against HVFA for detection of 30% or more superior visual field improvement after taping, warranting a corrective surgical intervention. In comparing hemi-VF in untaped eyes, both tests demonstrated relative obstruction to the field when comparing normal controls to severe ptosis (HVFA P < 0.05; MCHT P < 0.001), which proved sufficient to demonstrate percent improvement with taping. The secondary end point of patient satisfaction favored VR vision testing presentation mode in terms of comfort (P < 0.01), speed (P < 0.001), and overall experience (P < 0.01). This pilot trial supports the use of MCHT for the quantitative measurement of visual field loss owing to ptosis and the reversibility of ptosis that is tested when conducting a presurgical evaluation. We believe the adoption of MCHT testing in oculoplastic clinics could decrease patient burden and accelerate time to corrective treatment. In this study, we look at vision field outputs in patients with ptosis to evaluate its severity and improvement with eyelid taping on a low-profile VR-based technology and compare it with HVFA. Our results demonstrate that alternative, portable technologies such as VR can be used to grade the degree of ptosis and determine whether ptosis surgery could provide a significant superior visual field improvement of 30% or more, all while ensuring a more comfortable experience and faster testing time.
Identifiants
pubmed: 36282119
pii: 2783790
doi: 10.1167/tvst.11.10.35
pmc: PMC9617504
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Références
Indian J Ophthalmol. 2009 May-Jun;57(3):207-11
pubmed: 19384015
Clin Ophthalmol. 2017 Aug 07;11:1431-1443
pubmed: 28848325
Ophthalmic Plast Reconstr Surg. 1989;5(3):171-5
pubmed: 2487216
PLoS One. 2017 Mar 29;12(3):e0174607
pubmed: 28355310
PLoS One. 2016 Jan 04;11(1):e0145069
pubmed: 26727468
Ophthalmology. 1995 Jun;102(6):924-8
pubmed: 7777300
Transl Vis Sci Technol. 2021 Mar 1;10(3):20
pubmed: 34003954
Biomed Res Int. 2014;2014:206082
pubmed: 25050326
Community Eye Health. 2012;25(79-80):66-70
pubmed: 23520423
Digit Health. 2022 May 6;8:20552076221090042
pubmed: 35558637
Aesthetic Plast Surg. 2003 May-Jun;27(3):193-204
pubmed: 12925861
Eye (Lond). 2011 Mar;25(3):365-9
pubmed: 21252946
Clin Ophthalmol. 2018 Dec 12;12:2597-2606
pubmed: 30587906
Orbit. 2013 Aug;32(4):231-4
pubmed: 23662688
Invest Ophthalmol Vis Sci. 2012 Oct 09;53(11):7010-7
pubmed: 22952121
Arch Plast Surg. 2022 Jan;49(1):19-24
pubmed: 35086303
Ophthalmology. 1999 Sep;106(9):1705-12
pubmed: 10485538
Br J Ophthalmol. 2001 Jan;85(1):99-101
pubmed: 11133723
Clin Ophthalmol. 2019 Mar 14;13:501-513
pubmed: 30936681
Arch Ophthalmol. 1996 Jan;114(1):19-22
pubmed: 8540846
Curr Opin Ophthalmol. 2005 Dec;16(6):351-5
pubmed: 16264345
Arch Ophthalmol. 2000 Jan;118(1):65-9
pubmed: 10636416
Ophthalmology. 2011 Dec;118(12):2510-7
pubmed: 22019388